Zymeworks Inc
ZYME
查看詳細走勢圖
26.860USD
+0.070+0.26%
收盤 12/24, 13:00（美東）報價延遲15分鐘
2.03B總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+0.26%
5天
+1.74%
1月
+2.60%
6月
+111.33%
今年開始到現在
+83.47%
1年
+89.96%
查看詳細走勢圖
TradingKey Zymeworks Inc股票評分
單位: USD 更新時間: 2025-12-24操作建議
Zymeworks Inc當前公司基本面數據相對健康，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名12/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價34.50。中期看，股價處於上升通道。近一個月，市場表現一般，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Zymeworks Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
13
分析師
買入
評級
34.500
目標均價
+30.63%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Zymeworks Inc亮點
亮點風險
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
業績增長期
公司處於發展階段，最新年度總收入76.30M美元
估值低估
公司最新PE估值-31.75，處於3年歷史低位
機構減倉
最新機構持股74.41M股，環比減少3.33%
PRFDX持倉
明星投資者PRFDX持倉，最新持倉4.94K股
Zymeworks Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Zymeworks Inc簡介
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
公司代碼ZYME
公司Zymeworks Inc
CEOGalbraith (Kenneth H)
網址https://www.zymeworks.com/
常見問題
Zymeworks Inc(ZYME)的當前股價是多少？
Zymeworks Inc(ZYME)的當前股價是 26.860。
Zymeworks Inc 的股票代碼是什麼？
Zymeworks Inc的股票代碼是ZYME。
Zymeworks Inc股票的52週最高點是多少？
Zymeworks Inc股票的52週最高點是28.490。
Zymeworks Inc股票的52週最低點是多少？
Zymeworks Inc股票的52週最低點是9.030。
Zymeworks Inc的市值是多少？
Zymeworks Inc的市值是2.03B。
Zymeworks Inc的淨利潤是多少？
Zymeworks Inc的淨利潤為-122.69M。
現在Zymeworks Inc(ZYME)的股票是買入、持有還是賣出？
根據分析師評級，Zymeworks Inc(ZYME)的總體評級為買入，目標價格為34.500。
Zymeworks Inc(ZYME)股票的每股收益（EPS TTM）是多少
Zymeworks Inc(ZYME)股票的每股收益（EPS TTM）是-0.846。
相關品種
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
